A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

被引：24

作者：

Daver, Naval G. ^{[1
]}

Erba, Harry P. ^{[2
]}

Papadantonakis, Nikolaos ^{[2
]}

DeAngelo, Daniel J. ^{[3
]}

Wang, Eunice S. ^{[4
]}

Konopleva, Marina Y. ^{[1
]}

Sloss, Callum M. ^{[5
]}

Culm-Merdek, Kerry ^{[5
]}

Zweidler-McKay, Patrick A. ^{[5
]}

Kantarjian, Hagop M. ^{[6
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA

[5] ImmunoGen Inc, Waltham, MA USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1182/blood-2018-99-112955

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4